

# Karina Dahl Steffensen

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6806005/karina-dahl-steffensen-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

90  
papers

2,340  
citations

24  
h-index

47  
g-index

100  
ext. papers

2,990  
ext. citations

4.3  
avg, IF

4.88  
L-index

#	Paper	IF	Citations
90	Prognostic Impact of Circulating Methylated Homeobox A9 DNA in Patients Undergoing Treatment for Recurrent Ovarian Cancer.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1
89	Shared Decision Making with Acutely Hospitalized, Older Poly-Medicated Patients: A Mixed-Methods Study in an Emergency Department. <i>International Journal of Environmental Research and Public Health</i> , <b>2022</b> , 19, 6429	4.6	
88	What Works in Implementing Patient Decision Aids in Routine Clinical Settings? A Rapid Realist Review and Update from the International Patient Decision Aid Standards Collaboration. <i>Medical Decision Making</i> , <b>2021</b> , 41, 907-937	2.5	21
87	PractitionersViews on shared decision-making implementation: A qualitative study. <i>PLoS ONE</i> , <b>2021</b> , 16, e0259844	3.7	0
86	The PROMova study comparing active and passive use of patient-reported outcome measures in ovarian cancer follow-up: effect on patient-perceived involvement, satisfaction with care, and usefulness. <i>Acta Oncologica</i> , <b>2021</b> , 60, 434-443	3.2	0
85	Shared decision making with breast cancer patients: impact on patient engagement and fear of recurrence. Protocol for a Danish randomized trial in radiotherapy (DBCG RT SDM). <i>Acta Oncologica</i> , <b>2021</b> , 60, 1032-1037	3.2	0
84	Treosulfan in platinum-resistant ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2021</b> , 31, 1045-1051	3.5	
83	Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival. <i>European Journal of Cancer</i> , <b>2021</b> , 149, 128-133	7.5	4
82	Systematic Development of Patient Decision Aids: An Update from the IPDAS Collaboration. <i>Medical Decision Making</i> , <b>2021</b> , 41, 736-754	2.5	4
81	Association of patient-reported outcomes and ovarian cancer recurrence. <i>International Journal of Gynecological Cancer</i> , <b>2021</b> , 31, 1248-1259	3.5	1
80	Providing Balanced Information about Options in Patient Decision Aids: An Update from the International Patient Decision Aid Standards. <i>Medical Decision Making</i> , <b>2021</b> , 41, 780-800	2.5	2
79	Perspectives, fears and expectations of patients with gynaecological cancers during the COVID-19 pandemic: A Pan-European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGE). <i>Cancer Medicine</i> , <b>2021</b> , 10, 208-219	4.8	31
78	ePRO-based individual follow-up care for women treated for early breast cancer: impact on service use and workflows. <i>Journal of Cancer Survivorship</i> , <b>2021</b> , 15, 485-496	5.1	1
77	The impact of shared decision making on time consumption and clinical decisions. A prospective cohort study. <i>Patient Education and Counseling</i> , <b>2021</b> , 104, 1560-1567	3.1	5
76	Trust-Based Partnerships Are Essential - and Achievable - in Health Care Service. <i>Mayo Clinic Proceedings</i> , <b>2021</b> , 96, 1896-1906	6.4	3
75	Progression-free survival by investigator versus blinded independent central review in newly diagnosed patients with high-grade serous ovarian cancer: Analysis of the VELIA/GOG-3005 trial. <i>Gynecologic Oncology</i> , <b>2021</b> , 162, 375-381	4.9	1
74	HOXA9-methylated DNA as a diagnostic biomarker of ovarian malignancy. <i>Biomarkers in Medicine</i> , <b>2021</b> , 15, 1309-1317	2.3	0

73	Analysis of HOXA9 methylated ctDNA in ovarian cancer using sense-antisense measurement. <i>Clinica Chimica Acta</i> , <b>2021</b> , 522, 152-157	6.2	1
72	The challenge of involving old patients with polypharmacy in their medication during hospitalization in a medical emergency department: An ethnographic study.. <i>PLoS ONE</i> , <b>2021</b> , 16, e0261325	3.7	1
71	Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy. <i>Journal of Ovarian Research</i> , <b>2020</b> , 13, 59	5.5	3
70	Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma. <i>Acta Oncologica</i> , <b>2020</b> , 59, 652-659	3.2	13
69	Use of PROM during follow-up of patients with ovarian cancer: the PROMova study protocol. <i>International Journal of Gynecological Cancer</i> , <b>2020</b> , 30, 1444-1449	3.5	2
68	Satisfaction with care and adherence to treatment when using patient reported outcomes to individualize follow-up care for women with early breast cancer - a pilot randomized controlled trial. <i>Acta Oncologica</i> , <b>2020</b> , 59, 444-452	3.2	5
67	Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer. <i>European Journal of Cancer</i> , <b>2020</b> , 125, 121-129	7.5	20
66	Shared decision making in high-grade glioma patients-a systematic review. <i>Neuro-Oncology Practice</i> , <b>2020</b> , 7, 589-598	2.2	0
65	Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 86, 751-759	3.5	1
64	Blood natural killer cells during treatment in recurrent ovarian cancer. <i>Acta Oncologica</i> , <b>2020</b> , 59, 1365-1373	3.3	2
63	Cabazitaxel - A Treatment Option in Recurrent Platinum-resistant Ovarian Cancer. <i>Anticancer Research</i> , <b>2020</b> , 40, 5255-5261	2.3	2
62	Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 2403-2415	59.2	334
61	Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer. <i>Translational Oncology</i> , <b>2019</b> , 12, 968-972	4.9	10
60	The impact of a patient decision aid on shared decision-making behaviour in oncology care and pulmonary medicine-A field study based on real-life observations. <i>Journal of Evaluation in Clinical Practice</i> , <b>2019</b> , 25, 1121-1130	2.5	6
59	The promise of shared decision making in healthcare. <i>AMS Review</i> , <b>2019</b> , 9, 105-109	3	5
58	A prospective cohort study of shared decision making in lung cancer diagnostics: Impact of using a patient decision aid. <i>Patient Education and Counseling</i> , <b>2019</b> , 102, 1961-1968	3.1	8
57	Are patient-reported outcomes useful in post-treatment follow-up care for women with early breast cancer? A scoping review. <i>Patient Related Outcome Measures</i> , <b>2019</b> , 10, 117-127	2.9	10
56	Characteristics of patients with cervical cancer during pregnancy: a multicenter matched cohort study. An initiative from the International Network on Cancer, Infertility and Pregnancy. <i>International Journal of Gynecological Cancer</i> , <b>2019</b> ,	3.5	20

55	What matters in clinical trial decision-making: a systematic review of interviews exploring cancer patients' experiences. <i>Scandinavian Journal of Caring Sciences</i> , <b>2019</b> , 33, 266-278	2.3	9
54	Proactive use of PROMs in ovarian cancer survivors: a systematic review. <i>Journal of Ovarian Research</i> , <b>2019</b> , 12, 63	5.5	8
53	Shared decision making when patients consider surgery for lumbar herniated disc: development and test of a patient decision aid. <i>BMC Medical Informatics and Decision Making</i> , <b>2019</b> , 19, 190	3.6	5
52	Tissue immune response in epithelial ovarian carcinoma.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2625-2625	2.5	1
51	Long Non-coding RNAs Involved in Resistance to Chemotherapy in Ovarian Cancer. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 1549	5.3	26
50	A design-led patient campaign development process for disseminating the concept of shared decision making. <i>Design for Health</i> , <b>2019</b> , 3, 305-323	0.8	0
49	Factors Affecting Patient Decision-making on Surgery for Lumbar Disc Herniation. <i>Spine</i> , <b>2019</b> , 44, 143-149	1.9	17
48	Delta tocotrienol in recurrent ovarian cancer. A phase II trial. <i>Pharmacological Research</i> , <b>2019</b> , 141, 392-396	6.2	29
47	Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. <i>Lancet Oncology</i> , <b>2018</b> , 19, 337-346	21.7	132
46	How participatory action research changed our view of the challenges of shared decision-making training. <i>Patient Education and Counseling</i> , <b>2018</b> , 101, 639-646	3.1	8
45	Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status. <i>Cancer Treatment and Research Communications</i> , <b>2018</b> , 14, 7-12	2	14
44	Maternal and obstetrical outcome in 35 cases of well-differentiated thyroid carcinoma during pregnancy. <i>Laryngoscope</i> , <b>2018</b> , 128, 1493-1500	3.6	14
43	Methylated circulating tumor DNA as a potential marker of PARP inhibitor efficiency in BRCA mutated ovarian cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 5540-5540	2.2	2
42	Experiences of involvement in decision-making for patients with breast cancer. A phenomenological-hermeneutical study. <i>European Journal for Person Centered Healthcare</i> , <b>2018</b> , 6, 237	1.3	2
41	Axillary staging for breast cancer during pregnancy: feasibility and safety of sentinel lymph node biopsy. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 168, 551-557	4.4	21
40	Lessons in Integrating Shared Decision-Making Into Cancer Care. <i>Journal of Oncology Practice</i> , <b>2018</b> , 14, 229-235	3.1	32
39	Clopidogrel-Paclitaxel Drug-Drug Interaction: A Pharmacoepidemiologic Study. <i>Clinical Pharmacology and Therapeutics</i> , <b>2017</b> , 102, 547-553	6.1	19
38	Melanoma during pregnancy: a report of 60 pregnancies complicated by melanoma. <i>Melanoma Research</i> , <b>2017</b> , 27, 218-223	3.3	14

37	Implementing shared decision making in Denmark: First steps and future focus areas. <i>Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen</i> , <b>2017</b> , 123-124, 36-40	1.4	14
36	The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection. <i>International Journal of Gynecological Pathology</i> , <b>2017</b> , 36, 180-189	3.2	25
35	Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study. <i>International Journal of Gynecological Cancer</i> , <b>2017</b> , 27, 1842-1849	3.5	27
34	The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab. <i>International Journal of Gynecological Cancer</i> , <b>2016</b> , 26, 1390-8	3.5	14
33	Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer. <i>Oncology Letters</i> , <b>2016</b> , 11, 3967-3974	2.6	11
32	Post-mortem testing; germline BRCA1/2 variant detection using archival FFPE non-tumor tissue. A new paradigm in genetic counseling. <i>European Journal of Human Genetics</i> , <b>2016</b> , 24, 1104-11	5.3	7
31	Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 2611-8	7.5	37
30	Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression. <i>International Journal of Oncology</i> , <b>2014</b> , 44, 1736-44	4.4	23
29	Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting. <i>International Journal of Gynecological Cancer</i> , <b>2014</b> , 24, 394-403	3.5	135
28	Plasma HER2 amplification in cell-free DNA during neoadjuvant chemotherapy in breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2013</b> , 139, 995-1003	4.9	23
27	The strong prognostic value of KELIM, a model-based parameter from CA 125 kinetics in ovarian cancer: data from CALYPSO trial (a GINECO-GCIG study). <i>Gynecologic Oncology</i> , <b>2013</b> , 130, 289-94	4.9	13
26	Predicting brain metastases of breast cancer based on serum S100B and serum HER2. <i>Oncology Letters</i> , <b>2013</b> , 6, 1265-1270	2.6	8
25	Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study. <i>International Journal of Gynecological Cancer</i> , <b>2013</b> , 23, 73-80	3.5	19
24	Quantitative detection of HER2 protein concentration in breast cancer tissue does not increase the number of patients eligible for adjuvant HER2-targeted therapy. <i>Oncology Reports</i> , <b>2013</b> , 29, 1475-82	3.5	5
23	Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab. <i>Journal of Ovarian Research</i> , <b>2012</b> , 5, 23	5.5	24
22	Platelet-Derived Growth Factor Gene Polymorphisms in Patients With Ovarian Cancer. <i>Clinical Ovarian and Other Gynecologic Cancer</i> , <b>2012</b> , 5, 10-16		1
21	Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 133, 257-65	4.4	27
20	Immunohistochemical expression of platelet-derived growth factor receptors in ovarian cancer patients with long-term follow-up. <i>Pathology Research International</i> , <b>2012</b> , 2012, 851432		9

19	The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients. <i>International Journal of Gynecological Cancer</i> , <b>2012</b> , 22, 1474-82	3.5	21
18	The Prognostic Value of Syndecan-1 in Ovarian Cancer Patients with Long-Term Follow up. <i>Clinical Ovarian Cancer &amp; Other Gynecologic Malignancies</i> , <b>2011</b> , 4, 12-18		3
17	Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovarian cancer patients. <i>International Journal of Gynecological Cancer</i> , <b>2011</b> , 21, 1040-7	3.5	40
16	Prevalence of epithelial ovarian cancer stem cells correlates with recurrence in early-stage ovarian cancer. <i>Journal of Oncology</i> , <b>2011</b> , 2011, 620523	4.5	63
15	Gynecologic oncology training systems in Europe: a report from the European network of young gynaecological oncologists. <i>International Journal of Gynecological Cancer</i> , <b>2011</b> , 21, 1500-6	3.5	13
14	Supraclavicular recurrence after early breast cancer: a curable condition?. <i>Breast Cancer Research and Treatment</i> , <b>2011</b> , 125, 815-22	4.4	28
13	VEGF in the Development of Ovarian Malignancy. <i>Clinical Ovarian Cancer &amp; Other Gynecologic Malignancies</i> , <b>2011</b> , 4, 19-25		3
12	Estimation of immunohistochemical expression of VEGF in ductal carcinomas of the breast. <i>Journal of Histochemistry and Cytochemistry</i> , <b>2011</b> , 59, 750-60	3.4	24
11	Improved classification of epithelial ovarian cancer: results of 3 danish cohorts. <i>International Journal of Gynecological Cancer</i> , <b>2011</b> , 21, 1592-600	3.5	30
10	DNA-repair ERCC1 Gene Polymorphisms in Epithelial Ovarian Cancer and Relation to Platinum Resistance and Survival. <i>Journal of Cancer Therapy</i> , <b>2011</b> , 02, 140-147	0.2	6
9	Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer. <i>BMC Cancer</i> , <b>2010</b> , 10, 185	4.8	5
8	The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2010</b> , 117, 109-16	4.9	84
7	The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. <i>Gynecologic Oncology</i> , <b>2010</b> , 118, 167-71	4.9	44
6	Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. <i>Cell Cycle</i> , <b>2009</b> , 8, 158-66	4.7	398
5	The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2009</b> , 19, 820-5	3.5	59
4	Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2009</b> , 19, 578-84	3.5	27
3	Cancers take their Toll--the function and regulation of Toll-like receptors in cancer cells. <i>Oncogene</i> , <b>2008</b> , 27, 225-33	9.2	168
2	Preoperative Serum Levels of Epidermal Growth Factor Receptor, HER2, and Vascular Endothelial Growth Factor in Malignant and Benign Ovarian Tumors. <i>Clinical Ovarian Cancer &amp; Other Gynecologic Malignancies</i> , <b>2008</b> , 1, 127-134		4

- 1 Mutant epidermal growth factor receptor in benign, borderline, and malignant ovarian tumors. *Clinical Cancer Research*, **2008**, 14, 3278-82 12.9 26